Class information for: |
Basic class information |
Hierarchy of classes |
The table includes all classes above and classes immediately below the current class. |
| Cluster id | Level | Cluster label | #P |
|---|---|---|---|
| 10 | 4 | IMMUNOLOGY//TRANSPLANTATION//RHEUMATOLOGY | 1369268 |
| 17 | 3 | IMMUNOLOGY//JOURNAL OF IMMUNOLOGY//IMMUNOL | 124793 |
| 335 | 2 | CTLA 4//PD L1//PD 1 | 18269 |
| 17504 | 1 | CD30//SOLUBLE CD30//SCD30 | 623 |
Terms with highest relevance score |
| rank | Category | termType | chi_square | shrOfCwithTerm | shrOfTermInClass | termInClass |
|---|---|---|---|---|---|---|
| 1 | CD30 | authKW | 2027991 | 22% | 29% | 138 |
| 2 | SOLUBLE CD30 | authKW | 1911469 | 7% | 82% | 46 |
| 3 | SCD30 | authKW | 1862444 | 8% | 78% | 47 |
| 4 | CD30 LIGAND | authKW | 745010 | 3% | 82% | 18 |
| 5 | CD30L | authKW | 346876 | 2% | 57% | 12 |
| 6 | CD153 | authKW | 202350 | 1% | 100% | 4 |
| 7 | SOLUBLE CD30 SCD30 | authKW | 151763 | 0% | 100% | 3 |
| 8 | SGN 35 | authKW | 130454 | 1% | 37% | 7 |
| 9 | CANCER BIOTHERAPY | authKW | 113814 | 1% | 38% | 6 |
| 10 | BRENTUXIMAB VEDOTIN | authKW | 105911 | 3% | 12% | 17 |
Web of Science journal categories |
| chi_square_rank | Category | chi_square | shrOfCwithTerm | shrOfTermInClass | termInClass |
|---|---|---|---|---|---|
| 1 | Immunology | 4662 | 41% | 0% | 258 |
| 2 | Transplantation | 2487 | 13% | 0% | 83 |
| 3 | Hematology | 1122 | 13% | 0% | 84 |
| 4 | Oncology | 915 | 21% | 0% | 133 |
| 5 | Allergy | 706 | 5% | 0% | 32 |
| 6 | Pathology | 354 | 7% | 0% | 45 |
| 7 | Medicine, Research & Experimental | 182 | 8% | 0% | 47 |
| 8 | Surgery | 106 | 9% | 0% | 57 |
| 9 | Cell Biology | 81 | 8% | 0% | 49 |
| 10 | Medical Laboratory Technology | 77 | 2% | 0% | 13 |
Address terms |
| chi_square_rank | term | chi_square | shrOfCwithTerm | shrOfTermInClass | termInClass |
|---|---|---|---|---|---|
| 1 | IST TIPIZZAZ TISSUTALE PROBLEMI DIALISI | 101171 | 1% | 50% | 4 |
| 2 | ROTILIO | 67449 | 0% | 67% | 2 |
| 3 | AO CITTA DELLA SALUTE E DELLA SCI | 50588 | 0% | 100% | 1 |
| 4 | ASL 4 AQUILA | 50588 | 0% | 100% | 1 |
| 5 | BEIJING TONGEN HOSP | 50588 | 0% | 100% | 1 |
| 6 | BETH ISRAEL DEACONESS MED HEMATOPATHOL | 50588 | 0% | 100% | 1 |
| 7 | BIOL MOL ESTRUTUAL | 50588 | 0% | 100% | 1 |
| 8 | CANC ADV BIOTECHNOL | 50588 | 0% | 100% | 1 |
| 9 | CANC SCI TREMONA RD | 50588 | 0% | 100% | 1 |
| 10 | CARDIAC TRANSPLANTAT SURG SERV | 50588 | 0% | 100% | 1 |
Journals |
| chi_square_rank | term | chi_square | shrOfCwithTerm | shrOfTermInClass | termInClass |
|---|---|---|---|---|---|
| 1 | TRANSPLANT IMMUNOLOGY | 15857 | 3% | 2% | 19 |
| 2 | CANCER BIOTHERAPY AND RADIOPHARMACEUTICALS | 8730 | 3% | 1% | 16 |
| 3 | CURRENT HEMATOLOGIC MALIGNANCY REPORTS | 1287 | 0% | 1% | 3 |
| 4 | IMMUNITY & AGEING | 1166 | 0% | 1% | 2 |
| 5 | CLINICAL AND EXPERIMENTAL IMMUNOLOGY | 1116 | 3% | 0% | 16 |
| 6 | LEUKEMIA & LYMPHOMA | 1084 | 2% | 0% | 13 |
| 7 | CYTOKINES AND MOLECULAR THERAPY | 935 | 0% | 2% | 1 |
| 8 | FUNDAMENTAL AND CLINICAL IMMUNOLOGY | 855 | 0% | 2% | 1 |
| 9 | TRANSPLANTATION | 854 | 3% | 0% | 18 |
| 10 | JOURNAL OF IMMUNOLOGY | 694 | 4% | 0% | 28 |
Author Key Words |
| chi_square_rank | term | chi_square | shrOfCwithTerm | shrOfTermInClass | termInClass | LCSH search | Wikipedia search |
|---|---|---|---|---|---|---|---|
| 1 | CD30 | 2027991 | 22% | 29% | 138 | Search CD30 | Search CD30 |
| 2 | SOLUBLE CD30 | 1911469 | 7% | 82% | 46 | Search SOLUBLE+CD30 | Search SOLUBLE+CD30 |
| 3 | SCD30 | 1862444 | 8% | 78% | 47 | Search SCD30 | Search SCD30 |
| 4 | CD30 LIGAND | 745010 | 3% | 82% | 18 | Search CD30+LIGAND | Search CD30+LIGAND |
| 5 | CD30L | 346876 | 2% | 57% | 12 | Search CD30L | Search CD30L |
| 6 | CD153 | 202350 | 1% | 100% | 4 | Search CD153 | Search CD153 |
| 7 | SOLUBLE CD30 SCD30 | 151763 | 0% | 100% | 3 | Search SOLUBLE+CD30+SCD30 | Search SOLUBLE+CD30+SCD30 |
| 8 | SGN 35 | 130454 | 1% | 37% | 7 | Search SGN+35 | Search SGN+35 |
| 9 | CANCER BIOTHERAPY | 113814 | 1% | 38% | 6 | Search CANCER+BIOTHERAPY | Search CANCER+BIOTHERAPY |
| 10 | BRENTUXIMAB VEDOTIN | 105911 | 3% | 12% | 17 | Search BRENTUXIMAB+VEDOTIN | Search BRENTUXIMAB+VEDOTIN |
Core articles |
The table includes core articles in the class. The following variables is taken into account for the relevance score of an article in a cluster c: (1) Number of references referring to publications in the class. (2) Share of total number of active references referring to publications in the class. (3) Age of the article. New articles get higher score than old articles. (4) Citation rate, normalized to year. |
Classes with closest relation at Level 1 |